×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GLMD – galmed pharmaceuticals ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GLMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
08:46 am
glmd
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH [Yahoo! Finance]
Medium
Report
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH [Yahoo! Finance]
12/4
08:30 am
glmd
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Low
Report
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
12/1
08:30 am
glmd
Galmed Issues CEO Letter to Shareholders
Low
Report
Galmed Issues CEO Letter to Shareholders
11/26
08:30 am
glmd
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
11/18
08:30 am
glmd
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Medium
Report
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
11/17
09:22 am
glmd
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro [Yahoo! Finance]
High
Report
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro [Yahoo! Finance]
11/17
08:30 am
glmd
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
High
Report
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
08:42 am
glmd
Form 6-K Galmed Pharmaceuticals For: Dec 04
Medium
Report
Form 6-K Galmed Pharmaceuticals For: Dec 04
12/1
08:39 am
glmd
Form 6-K Galmed Pharmaceuticals For: Dec 01
Medium
Report
Form 6-K Galmed Pharmaceuticals For: Dec 01
11/26
08:57 am
glmd
Form 6-K Galmed Pharmaceuticals For: Sep 30
High
Report
Form 6-K Galmed Pharmaceuticals For: Sep 30
11/18
08:49 am
glmd
Form 6-K Galmed Pharmaceuticals For: Nov 18
Low
Report
Form 6-K Galmed Pharmaceuticals For: Nov 18
11/17
08:39 am
glmd
Form 6-K Galmed Pharmaceuticals For: Nov 17
Medium
Report
Form 6-K Galmed Pharmaceuticals For: Nov 17
11/7
04:52 pm
glmd
Form SCHEDULE 13G/A Galmed Pharmaceuticals Filed by: CVI Investments, Inc.
Low
Report
Form SCHEDULE 13G/A Galmed Pharmaceuticals Filed by: CVI Investments, Inc.
10/29
04:05 pm
glmd
Form 6-K Galmed Pharmaceuticals For: Oct 29
Low
Report
Form 6-K Galmed Pharmaceuticals For: Oct 29
10/28
04:05 pm
glmd
Form 6-K Galmed Pharmaceuticals For: Oct 28
Medium
Report
Form 6-K Galmed Pharmaceuticals For: Oct 28
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/2
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock.
29.3%
3/18 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 18.0%
3/13 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its price target lowered by analysts at B. Riley from $28.00 to $11.00. They now have a "buy" rating on the stock. 13.2%
10/31 Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 13.1%
1/7 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 11.9%
2/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $18.00 price target on the stock. 11.9%
1/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.3%
11/10 Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT [Yahoo! Finance News] 5.7%
8/5 Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.4%
8/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $20.00 price target on the stock. 3.9%
3/18 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 18.0%
3/13 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its price target lowered by analysts at B. Riley from $28.00 to $11.00. They now have a "buy" rating on the stock. 13.2%
10/31 Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 13.1%
1/7 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 11.9%
2/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $18.00 price target on the stock. 11.9%
1/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.3%
11/10 Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT [Yahoo! Finance News] 5.7%
8/5 Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.4%
8/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $20.00 price target on the stock. 3.9%
TOP News Decliners
3/12
Q4/2019 12/31/2019 EPS -0.390 ZacksConsensus -0.370 ActVsEst (0.020) - Miss
-19.5%
8/5 Form 6-K Galmed Pharmaceuticals For: Jun 30 -17.8%
7/22 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Laidlaw. They set a "buy" rating on the stock. -11.7%
2/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -11.1%
1/30 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock, down previously from $59.00. -11.1%
11/6 Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results -11.0%
10/23 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. -8.0%
5/7 Q1/2019 3/31/2019 EPS -0.170 ZacksConsensus -0.190 ActVsEst 0.020 - Beat -7.7%
3/5 Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12 -6.2%
3/17 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. -5.1%
8/5 Form 6-K Galmed Pharmaceuticals For: Jun 30 -17.8%
7/22 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Laidlaw. They set a "buy" rating on the stock. -11.7%
2/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -11.1%
1/30 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock, down previously from $59.00. -11.1%
11/6 Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results -11.0%
10/23 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. -8.0%
5/7 Q1/2019 3/31/2019 EPS -0.170 ZacksConsensus -0.190 ActVsEst 0.020 - Beat -7.7%
3/5 Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12 -6.2%
3/17 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: